Supernus Pharmaceuticals (SUPN) Receives a Buy from Piper Sandler

Piper Sandler analyst David Amsellem reiterated a Buy rating on Supernus Pharmaceuticals today and set a price target of $65.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Amsellem is a 4-star analyst with an average return of 7.2% and a 52.39% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Bristol-Myers Squibb.

In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $63.00 price target.

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $192.1 million and a GAAP net loss of $45.12 million. In comparison, last year the company earned a revenue of $175.69 million and had a net profit of $38.5 million

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SUPN in relation to earlier this year. Most recently, in October 2025, Jack Khattar, the President & CEO of SUPN sold 59,900.00 shares for a total of $3,029,336.39.